HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the year ended December 31, 2007. Nymox reported a net loss of $5,290,431, or $0.18 per share for the year ended December 31, 2007, compared to $4,893,685, or $0.18 per share for same period in 2006. The increase in net losses for the year is attributable to increased expenditures in research and development of products in the Company’s pipeline and to accounting requirements for stock option compensation. Product sales amounted to $412,923 for the year ended December 31, 2007, compared to $437,440 for the same period in 2006. The weighted average number of common shares at the year ended December 31, 2007 was 29,005,342, compared to 27,644,749 at December 31, 2006.
